Novartis b meningitis vaccine bexsero qualified for FDA breakthrough treatment
-
Last Update: 2014-04-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Ding Xiangyuan said on April 8, 2014 that Novartis awarded the company the b-meningitis vaccine bexsero breakthrough treatment drug qualification by the US FDA Novartis said in a April 7 statement that it plans to file a listing application for bexsero in the United States early in the second quarter of this year Bexsero is widely regarded as crucial to Novartis vaccine business, where Novartis has been catching up with GlaxoSmithKline, Sanofi and MSD In 2013, Novartis' vaccine business was the only one of the company's five business units to lose money The vaccine has been approved in Europe, Canada and Australia, and has been used in several universities in the United States to stop outbreaks of meningitis in schools Source address: http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
